Merus has been granted a patent for bispecific antibodies that can bind to epidermal growth factor receptor (EGFR) and MET Proto-Oncogene, Receptor Tyrosine Kinase (cMET). The antibodies may be in the IgG1 format and have a stoichiometry of 1:1. The patent also includes specific sequences for the variable domains of the antibodies. GlobalData’s report on Merus gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Merus, Personalized cancer vaccines was a key innovation area identified from patents. Merus's grant share as of September 2023 was 29%. Grant share is based on the ratio of number of grants to total number of patents.
Bispecific antibody for binding egfr and cmet receptors
A recently granted patent (Publication Number: US11773170B2) describes a bispecific antibody that can bind to two different proteins involved in cancer growth and progression. The antibody consists of two variable domains, one that can bind to the human epidermal growth factor receptor (EGFR) and another that can bind to the MET Proto-Oncogene, Receptor Tyrosine Kinase (cMET).
The first variable domain of the bispecific antibody contains a specific sequence of amino acids, including a CDR1 sequence (SYGIS), a CDR2 sequence (WISAYNANTNYAQKLQG), and a CDR3 sequence (DRHWHWWLDA). The second variable domain also contains specific sequences of amino acids, including a CDR1 sequence (TYSMN), a CDR2 sequence (WINTYTGDPTYAQGFTG), and a CDR3 sequence (ETYFYDRGGYPFDP).
The bispecific antibody is designed in an IgG1 format and has an anti-EGFR, anti-cMET stoichiometry of 1:1, meaning it can simultaneously bind to one molecule of EGFR and one molecule of cMET.
Additionally, the patent describes specific amino acid sequences in the heavy chain variable region of the second variable domain, which can be selected from a list of sequences provided in the patent.
Overall, this patent describes a bispecific antibody with specific binding capabilities to EGFR and cMET, which are both involved in cancer development and progression. The antibody's design and specific amino acid sequences make it a potentially valuable therapeutic tool for targeting these proteins in cancer treatment.
To know more about GlobalData’s detailed insights on Merus, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
